Who are Salmeterol and Fluticasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Seretide 500 Accuhaler, Salmeterol/ fluticasone propionate, Salmeterol and Salmeterol / Fluticasone, Salmeterol xinafoate/fluticasone propionate combination, Seretide® Accuhaler® 250/50 µg/actuation, Formoterol/Fluticasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salmeterol-and-fluticasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Salmeterol and Fluticasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salmeterol and Fluticasone (Salmeterol and Fluticasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Inhaled corticosteroid combination. Area: Respiratory / Pulmonology.

marketed Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor (salmeterol); glucocorticoid receptor (fluticasone) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol and Fluticasone (Salmeterol and Fluticasone) — GlaxoSmithKline. Salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone is a corticosteroid that reduces airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Salmeterol and Fluticasone TARGET	Salmeterol and Fluticasone	GlaxoSmithKline	marketed	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor (salmeterol); glucocorticoid receptor (fluticasone)
Seretide 500 Accuhaler	Seretide 500 Accuhaler	University of Southampton	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate	Salmeterol/ fluticasone propionate	GlaxoSmithKline	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol and Salmeterol / Fluticasone	Salmeterol and Salmeterol / Fluticasone	University of Rostock	marketed	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor / Glucocorticoid receptor
Salmeterol xinafoate/fluticasone propionate combination	Salmeterol xinafoate/fluticasone propionate combination	GlaxoSmithKline	marketed	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor (salmeterol); Glucocorticoid receptor (fluticasone propionate)
Seretide® Accuhaler® 250/50 µg/actuation	Seretide® Accuhaler® 250/50 µg/actuation	Chiesi Farmaceutici S.p.A.	phase 3	Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; Glucocorticoid receptor
Formoterol/Fluticasone	Formoterol/Fluticasone	Eurofarma Laboratorios S.A.	phase 3	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Inhaled corticosteroid combination class)

GlaxoSmithKline · 2 drugs in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
University of Rostock · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol and Fluticasone — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-and-fluticasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab